{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:10:43Z","timestamp":1763017843600,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00277-018-3283-z","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T20:52:33Z","timestamp":1519678353000},"page":"1229-1240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant"],"prefix":"10.1007","volume":"97","author":[{"given":"Mahmoud A.","family":"Elshenawy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Shahzad Rauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tusneem A.M.","family":"Elhassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfan","family":"Maghfoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-0944","authenticated-orcid":false,"given":"Saad","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"issue":"1","key":"3283_CR1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.1999.17.1.222","volume":"17","author":"M Andr\u00e9","year":"1999","unstructured":"Andr\u00e9 M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, Coiffier B, Colombat P, Cahn JY, Attal M, Fleury J, Milpied N, Nedellec G, Biron P, Tilly H, Jouet JP, Gisselbrecht for the Soci\u00e9t\u00e9 Franca C (1999) Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin\u2019s disease induction failure: a case-control study. Soci\u00e9t\u00e9 Francaise de Greffe de Moelle. J Clin Oncol 17(1):222\u2013229","journal-title":"J Clin Oncol"},{"issue":"8852","key":"3283_CR2","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al (1993) Dose intensification with autologous bone-marrow transplantation in relpased and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet (London, England) 341(8852):1051\u20131054","journal-title":"Lancet (London, England)"},{"issue":"2","key":"3283_CR3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1200\/JCO.1999.17.2.534","volume":"17","author":"HM Lazarus","year":"1999","unstructured":"Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ et al (1999) Autotransplants for Hodgkin\u2019s disease in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 17(2):534\u2013545","journal-title":"J Clin Oncol"},{"issue":"12","key":"3283_CR4","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.bbmt.2013.09.018","volume":"19","author":"T Hahn","year":"2013","unstructured":"Hahn T, McCarthy PL, Carreras J, Zhang MJ, Lazarus HM, Laport GG et al (2013) Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma. Biol Blood Marrow Transplant 19(12):1740\u20131744. https:\/\/doi.org\/10.1016\/j.bbmt.2013.09.018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"3283_CR5","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al (2016) Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood 128(12):1562\u20131566. https:\/\/doi.org\/10.1182\/blood-2016-02-699850","journal-title":"Blood"},{"issue":"18","key":"3283_CR6","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30(18):2183\u20132189. https:\/\/doi.org\/10.1200\/jco.2011.38.0410","journal-title":"J Clin Oncol"},{"issue":"12","key":"3283_CR7","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/bmt.2013.88","volume":"48","author":"S Akhtar","year":"2013","unstructured":"Akhtar S, Al-Sugair A, Abouzied M, Alkadhi Y, Dingle M, Abdelsalam M et al (2013) Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT. Bone Marrow Transplant 48(12):1530\u20131536. https:\/\/doi.org\/10.1038\/bmt.2013.88","journal-title":"Bone Marrow Transplant"},{"key":"3283_CR8","doi-asserted-by":"publisher","unstructured":"Bair SM, Strelec L, Nagle SJ, Nasta SD, Landsburg DJ, Mato AR et al (2017) Outcomes of patients with relapsed\/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: a retrospective analysis. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.24792","DOI":"10.1002\/ajh.24792"},{"issue":"9","key":"3283_CR9","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1093\/annonc\/mdt206","volume":"24","author":"C Martinez","year":"2013","unstructured":"Martinez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A et al (2013) Identification of prognostic factors predicting outcome in Hodgkin\u2019s lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 24(9):2430\u20132434. https:\/\/doi.org\/10.1093\/annonc\/mdt206","journal-title":"Ann Oncol"},{"issue":"3","key":"3283_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.bbmt.2011.07.020","volume":"18","author":"P Kaloyannidis","year":"2012","unstructured":"Kaloyannidis P, Voutiadou G, Baltadakis I, Tsirigotis P, Spyridonidis A, Repousis P et al (2012) Outcomes of Hodgkin\u2019s lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 18(3):451\u2013457. https:\/\/doi.org\/10.1016\/j.bbmt.2011.07.020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"3283_CR11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.bbmt.2011.08.012","volume":"18","author":"SF Keller","year":"2012","unstructured":"Keller SF, Kelly JL, Sensenig E, Andreozzi J, Oliva J, Rich L et al (2012) Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era. Biol Blood Marrow Transplant 18(4):640\u2013647. https:\/\/doi.org\/10.1016\/j.bbmt.2011.08.012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"3283_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","volume":"146","author":"AJ Moskowitz","year":"2009","unstructured":"Moskowitz AJ, Perales MA, Kewalramani T, Yahalom J, Castro-Malaspina H, Zhang Z et al (2009) Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. Br J Haematol 146(2):158\u2013163. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07727.x","journal-title":"Br J Haematol"},{"key":"3283_CR13","doi-asserted-by":"publisher","unstructured":"Crump M. Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program 2008: 326-333. doi: https:\/\/doi.org\/10.1182\/asheducation-2008.1.326","DOI":"10.1182\/asheducation-2008.1.326"},{"issue":"4","key":"3283_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/annonc\/mdi119","volume":"16","author":"A Sureda","year":"2005","unstructured":"Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ, Petit J, L\u00f3pez A, Lahuerta JJ, Carreras E, Garc\u00eda-Conde J, Garc\u00eda-Lara\u00f1a J, Cabrera R, Jarque I, Carrera D, Garc\u00eda-Ruiz JC, Pascual MJ, Rif\u00f3n J, Moraleda JM, P\u00e9rez-Equiza K, Alb\u00f3 C, D\u00edaz-Mediavilla J, Torres A, Torres P, Besalduch J, Mar\u00edn J, Mateos MV, Fern\u00e1ndez-Ra\u00f1ada JM, Sierra J, Conde E, Grupo Espa\u00f1ol de Linfomas\/Trasplante Aut\u00f3logo de M\u00e9dula Osea Cooperative Group (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse. Ann Oncol 16(4):625\u2013633","journal-title":"Ann Oncol"},{"issue":"7","key":"3283_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/sj.bmt.1703888","volume":"31","author":"O Paltiel","year":"2003","unstructured":"Paltiel O, Rubinstein C, Or R, Nagler A, Gordon L, Deutsch L et al (2003) Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplant 31(7):565\u2013569. https:\/\/doi.org\/10.1038\/sj.bmt.1703888","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"3283_CR16","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.V80.8.2142.2142","volume":"80","author":"JM Vose","year":"1992","unstructured":"Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J et al (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80(8):2142\u20132148","journal-title":"Blood"},{"issue":"19","key":"3283_CR17","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P et al (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma. J Clin Oncol 35(19):2125\u20132132. https:\/\/doi.org\/10.1200\/jco.2016.72.1316","journal-title":"J Clin Oncol"},{"issue":"4","key":"3283_CR18","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244\u20131253","journal-title":"J Clin Oncol"},{"issue":"21","key":"3283_CR19","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl VA (1998) Prognostic score for advanced Hodgkin\u2019s disease. International prognostic factors project on advanced Hodgkin\u2019s disease. N Engl J Med 339(21):1506\u20131514","journal-title":"N Engl J Med"},{"issue":"1","key":"3283_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s12032-014-0388-7","volume":"32","author":"MS Rauf","year":"2015","unstructured":"Rauf MS, Maghfoor I, Elhassan TA, Akhtar S (2015) High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin\u2019s lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy. Med Oncol (Northwood, London, England) 32(1):388. https:\/\/doi.org\/10.1007\/s12032-014-0388-7","journal-title":"Med Oncol (Northwood, London, England)"},{"issue":"3","key":"3283_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.bmt.1705239","volume":"37","author":"S Akhtar","year":"2006","unstructured":"Akhtar S, Tbakhi A, Humaidan H, El Weshi A, Rahal M, Maghfoor I (2006) ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 37(3):277\u2013282","journal-title":"Bone Marrow Transplant"},{"key":"3283_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M, Nozza A, Sarina B, Morenghi E, Castagna L, Tirelli U, Balzarotti M (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica 92:35\u201341","journal-title":"Haematologica"},{"issue":"9980","key":"3283_CR23","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH et al (2015) Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England) 385(9980):1853\u20131862. https:\/\/doi.org\/10.1016\/s0140-6736(15)60165-9","journal-title":"Lancet (London, England)"},{"key":"3283_CR24","doi-asserted-by":"publisher","unstructured":"Zagadailov EA, Corman S, Chirikov V, Johnson C, Macahilig C, Seal B et al. Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed\/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. Leuk Lymphoma 2017: 1\u20137. doi: https:\/\/doi.org\/10.1080\/10428194.2017.1382698","DOI":"10.1080\/10428194.2017.1382698"},{"issue":"19","key":"3283_CR25","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1002\/cncr.30818","volume":"123","author":"L Hui","year":"2017","unstructured":"Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X et al (2017) Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 123(19):3763\u20133771. https:\/\/doi.org\/10.1002\/cncr.30818","journal-title":"Cancer"},{"issue":"1","key":"3283_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/10428194.2017.1324160","volume":"59","author":"A Gautam","year":"2018","unstructured":"Gautam A, Zhu Y, Ma E, Lee SY, Zagadailov E, Teasell J et al (2018) Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat. Leuk Lymphoma 59(1):69\u201376. https:\/\/doi.org\/10.1080\/10428194.2017.1324160","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"3283_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372(4):311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa1411087","journal-title":"N Engl J Med"},{"key":"3283_CR28","doi-asserted-by":"publisher","unstructured":"Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J et al (2016) Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2016.67.3467","DOI":"10.1200\/jco.2016.67.3467"},{"issue":"5","key":"3283_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/bmt.2013.226","volume":"49","author":"MA Kharfan-Dabaja","year":"2014","unstructured":"Kharfan-Dabaja MA, Hamadani M, Sibai H, Savani BN (2014) Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all! Bone Marrow Transplant 49(5):599\u2013606. https:\/\/doi.org\/10.1038\/bmt.2013.226","journal-title":"Bone Marrow Transplant"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3283-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3283-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3283-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T18:52:50Z","timestamp":1603911170000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3283-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["3283"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3283-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2018,2,26]]},"assertion":[{"value":"28 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}